Segall Bryant & Hamill’s Vaxcyte PCVX Stock Holding History

Segall Bryant & Hamill’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.9M	Buy	187,269 +3,334	+2%	+$181K	0.13%	239
2026 Q1	$10.7M	Sell	183,935 -9,488	-5%	-$515K	0.15%	219
2025 Q4	$8.92M	Buy	193,423 +8,628	+5%	+$386K	0.12%	245
2025 Q3	$6.66M	Buy	184,795 +4,556	+3%	+$151K	0.09%	287
2025 Q2	$5.86M	Buy	180,239 +30,477	+20%	+$999K	0.08%	295
2025 Q1	$5.66M	Sell	149,762 -4,226	-3%	-$338K	0.09%	294
2024 Q4	$12.6M	Sell	153,988 -2,068	-1%	-$205K	0.17%	181
2024 Q3	$17.8M	Sell	156,056 -6,376	-4%	-$575K	0.24%	131
2024 Q2	$12.3M	Buy	162,432 +4,411	+3%	+$300K	0.22%	155
2024 Q1	$10.8M	Sell	158,021 -2,260	-1%	-$156K	0.2%	173
2023 Q4	$10.1M	Buy	+160,281	New	+$8.32M	0.19%	183

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Segall Bryant & Hamill's PCVX Position: Q2 2026 in Review

Segall Bryant & Hamill increased its Vaxcyte (PCVX) stake by 1.8% in Q2 2026, buying an estimated $181K and bringing the position to 187,269 shares worth $10.9M. The position accounts for 0.13% of the portfolio, ranked #239.

Segall Bryant & Hamill first reported a position in PCVX in Q4 2023 and has held it in 11 quarters since. The position peaked at $17.8M in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Segall Bryant & Hamill held 187,269 shares of Vaxcyte worth $10.9M as of Q2 2026.
Segall Bryant & Hamill bought 3,334 Vaxcyte shares in Q2 2026, an estimated $181K.
Vaxcyte made up 0.13% of Segall Bryant & Hamill's portfolio in Q2 2026, its #239 holding.
Segall Bryant & Hamill first reported a position in Vaxcyte in Q4 2023 and has held it in 11 quarters since.
Segall Bryant & Hamill's Vaxcyte position peaked at $17.8M in Q3 2024.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.